Clinical Outcomes of Hospitalized Immunocompromised Patients With COVID-19 and the Impact of Hyperinflammation: A Retrospective Cohort Study

Journal of Inflammation Research, Год журнала: 2025, Номер Volume 18, С. 3385 - 3397

Опубликована: Март 1, 2025

Purpose: Immunocompromised patients are at increased risk for severe outcomes from COVID-19 due to their altered immune responses, yet inflammatory profiles and the interplay between immunosuppression remain poorly understood. We aimed illustrate inflammation profile clinical of hospitalized immunocompromised with COVID-19. Methods: conducted a retrospective study using multicenter database included adult Corona virus disease 2019 (COVID-19) in China's late 2022 wave. Crude adjusted 28- 60-day mortality was compared two groups. Inflammatory phenotypes were evaluated by serum interleukin-6 (IL-6) C-reactive protein (CRP) level. The overt analyzed. Results: Among 4078 patients, 348 (8.5%) immunocompromised. had lower crude but higher 28-day (hazard ratio [HR] = 1.55; 95% CI 1.08 2.23) (HR 1.47; 1.05 2.06). Besides, developing hyperinflammation (odd [OR] =1.92; 1.47 2.50, p < 0.001). Moreover, mediated major part deleterious survival effect on Conclusion: Immunodeficiency not only increases short-term also predisposes hyperinflammation. complex immunosuppression, hyperinflammation, warrants more detailed profiling immunity this population. Keywords: COVID-19, in-hospital mortality,

Язык: Английский

---

SARS-CoV-2 Variants and Clinical Outcomes of Special Populations: A Scoping Review of the Literature

Viruses, Год журнала: 2024, Номер 16(8), С. 1222 - 1222

Опубликована: Июль 30, 2024

The ongoing COVID-19 pandemic has significantly impacted special populations, including immunocompromised individuals, people living with HIV (PLWHIV), pediatric patients, and those chronic liver disease (CLD). This scoping review aims to map the clinical outcomes of these vulnerable groups when infected various SARS-CoV-2 variants. identifies trends patterns, noting that early variants, such as Alpha Delta, are associated more severe outcomes, higher hospitalization mortality rates. In contrast, Omicron variant, despite its increased transmissibility, tends cause milder manifestations. highlights necessity for surveillance tailored healthcare interventions due heterogeneity patient populations evolving nature virus. Continuous monitoring adaptive strategies essential mitigate impact on high-risk groups.

Язык: Английский

---

Safety and Outcome of High-Flow Nasal Oxygen Therapy Outside ICU Setting in Hypoxemic Patients With COVID-19*

Critical Care Medicine, Год журнала: 2023, Номер 52(1), С. 31 - 43

Опубликована: Окт. 19, 2023

OBJECTIVE: High-flow nasal oxygen (HFNO) therapy is frequently applied outside ICU setting in hypoxemic patients with COVID-19. However, safety concerns limit more widespread use. We aimed to assess the and clinical outcomes of initiation HFNO COVID-19 on non-ICU wards. DESIGN: Prospective observational multicenter pragmatic study. SETTING: Respiratory wards ICUs 10 hospitals The Netherlands. PATIENTS: Adult treated for COVID-19-associated hypoxemia between December 2020 July 2021 were included. Patients treatment limitations excluded from this analysis. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Outcomes included intubation mortality rate, duration hospital stay, severity respiratory failure, complications. Using propensity-matched analysis, we compared who initiated versus those ICU. Six hundred eight included, whom 379 started ward 229 rate matched cohort ( n = 214 patients) was 53% 60% starters, respectively p 0.41). Mortality rates comparable groups (28-d [8% vs 13%], 0.28). ICU-free days significantly higher starters (21 17 d, < 0.001). No patient died before endotracheal intubation, failure surrounding invasive ventilation did not differ intubated (respiratory rate-oxygenation index 3.20 3.38; Pa o 2 :F io ratio 65 64 mm Hg; prone positioning after 81 78%; 25% ventilator-free at 28 d 15 13 all values > 0.05). CONCLUSIONS: In large COVID-19, safe, similar Furthermore, saved time without excess or complicated course. Our results indicate that should be further explored other diseases settings aiming preserve capacity healthcare costs.

Язык: Английский

---

Synergistic antimicrobial nanofiber membranes based on metal incorporated silica nanoparticles as advanced antimicrobial layers

RSC Advances, Год журнала: 2024, Номер 14(46), С. 33919 - 33940

Опубликована: Янв. 1, 2024

In this post-new-normal era, the public prioritizes preventive measures over curing, which is a constructive approach to staying healthy. study, an innovative antimicrobial membrane material has been developed, showcasing promising potential for various applications. The metal-doped silica nanoparticles (Ag, Cu, and Co) were incorporated into cellulose acetate (CA) polymer-based nanofiber using electrospinning technique. metal doped silanol network of nanoparticles. fabricated membranes underwent detailed characterization wide range techniques including PXRD, FTIR, Raman, SEM, TEM, TGA, tensile testing. These analyses provided compelling evidence confirming successful incorporation cellulose-based nanofibers. band gap energies CA mats lie below 3.00 eV, that they are visible light active. trimetallic nanohybrid exhibited lowest energy 2.84 proving self-sterilizing ability mats. DPPH assay further confirmed best radical scavenging activity by mat (91.77 ± 0.88%). was assessed bacterial ATCC strains

Язык: Английский

---

Clinical and Analytical Performance of ELISA Salivary Serologic Assay to Detect SARS-CoV-2 IgG in Children and Adults

Antibodies, Год журнала: 2024, Номер 13(1), С. 6 - 6

Опубликована: Янв. 5, 2024

Saliva is a promising matrix with several purposes. Our aim to verify if salivary anti-SARS-CoV-2 antibody determination suitable for monitoring immune responses. One hundred eighty-seven subjects were enrolled at University-Hospital Padova: 105 females (56.1%) and 82 males (43.9%), 95 (50.8%) children 92 (49.2%) adults. Subjects self-collected saliva using Salivette; nineteen collected three different samples within the day. A serum sample was obtained all individuals. The N/S IgG (sal-IgG) S-RBD (ser-IgG) used determining antibodies. mean (min-max) age 9.0 (1-18) 42.5 (20-61) Of 187 samples, 63 negative sal-IgG (33.7%), while 7 ser-IgG (3.7%). Spearman's correlation 0.56 (

Язык: Английский

---

Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in France

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Март 15, 2024

ABSTRACT An economic evaluation was conducted to predict the and clinical burden of vaccinating immunocompromised (IC) individuals aged ≥30 years with mRNA-1273 variant-adapted COVID-19 vaccines in Fall 2023 Spring 2024 versus BNT162b2 France. The number symptomatic infections, hospitalizations, deaths, long COVID cases, costs quality-adjusted life (QALYs) estimated using a static decision-analytic model. Predicted vaccine effectiveness (VE) were based on real-world data from prior versions, suggesting higher protection against infection hospitalization vaccines. VE estimates combined incidence probability severe outcomes. Uncertainty surrounding VE, coverage, incidence, mortality rates, QALYs tested sensitivity analyses. is predicted prevent an additional 3,882 357 81 326 cases when compared 230,000 IC individuals. This translates €10.1 million cost-savings societal perspective 645 saved. Results consistent across all analyses most sensitive variations coverage. These findings highlight importance increasing ability induce levels formulations this vulnerable population.

Язык: Английский

---

Shielding the immunocompromised: COVID-19 prevention strategies for patients with primary and secondary immunodeficiencies

Vaccine, Год журнала: 2025, Номер 51, С. 126853 - 126853

Опубликована: Фев. 12, 2025

Язык: Английский

---

60-day mortality and the role of SARS-CoV-2 in hospital admissions of immunocompromised patients during later Omicron period: a population-based study in Sweden

Infectious Diseases, Год журнала: 2025, Номер unknown, С. 1 - 13

Опубликована: Фев. 16, 2025

Background Real-world data on hospitalised SARS-CoV-2-positive patients are important for post-pandemic preventive measures.

Язык: Английский

---

Population-Level Risks for HIV Mortality During the COVID-19 Pandemic in the United States by Demographic Characteristics and Medicaid Access, 2020‒2021

American Journal of Public Health, Год журнала: 2025, Номер 115(4), С. 579 - 587

Опубликована: Март 12, 2025

Objectives. To evaluate the impact of COVID-19 pandemic on HIV mortality rates with a focus demographic predictors and Medicaid access. Methods. Using Wide-Ranging Online Data for Epidemiologic Research, we conducted descriptive study comparing in United States 2 years before (2018–2019) initial (2020–2021), identifying factors during pandemic. Results. During first pandemic, crude death increased then decreased marginally. together contributed to 11% rate. While African Americans had higher rate, there was slight decrease Nonelderly adults expansion states lower than those nonexpansion states. Conclusions. Contrary concerns, found no substantial increase mortality. A observed persisting racial disparities that expanded Medicaid. Public Health Implications. The findings can inform development policies address through targeted system-level interventions vulnerable populations, such as Ryan White Program services. ( Am J Health. 2025;115(4):579–587. https://doi.org/10.2105/AJPH.2024.307916 )

Язык: Английский

---

Risk of Severe COVID-19 in Four Immunocompromised Populations: A French Expert Perspective

Infectious Diseases and Therapy, Год журнала: 2025, Номер unknown

Опубликована: Март 18, 2025

Immunocompromised patients are disproportionately impacted by severe disease, hospitalization, and mortality associated with coronavirus disease 2019 (COVID-19). To optimize the management of these in clinical practice, we convened an expert panel to review current evidence on acute respiratory syndrome 2 (SARS-CoV-2) vaccine responses COVID-19 immunocompromised populations. We identified four main groups—solid organ transplant recipients, receiving allogeneic hematopoietic stem cell transplantation or chimeric antigen receptor (CAR) T therapy, treated for hematologic malignancies, inflammatory diseases—who mount suboptimal humoral SARS-CoV-2 vaccination at increased risk COVID-19-related outcomes. A wide range factors were reduced and/or poor outcomes, most commonly older age, comorbidities, type number immunosuppressive therapies. believe that early identification close monitoring at-risk patients, plus regular booster vaccinations, prophylactic monoclonal antibody non-pharmacologic prevention measures, prompt antiviral treatment, other mitigation strategies, critical protect against infection COVID-19. Although people will fully recover from COVID-19, who less able fight more likely be hospitalized die improve treatment people, 10 experts France met discuss latest medical research this area. The focused groups people: (1) transplants; (2) transplants therapy; (3) being blood cancers; (4) diseases (such as rheumatoid arthritis). These protected after develop forms pre-existing conditions diabetes, obesity, heart, lung, kidney disease), immunosuppressants. agreed it is important quickly identify clinic, so they can receive vaccines every 6 months. For unable build up their immunity vaccination, treatments also used prevent infection. In recommend using therapies nirmatrelvir/ritonavir remdesivir) becoming severe. addition measures mask wearing social distancing), strategies help

Язык: Английский

---